Long-acting version of Baxter’s hemophilia drug succeeds in study




Whatsapp News

Baxter's hemophilia drugBaxter International Inc said a potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

The experimental drug, BAX 855, being tested as a preventive therapy and an -demand treatment in 138 previously treated adolescent and adult hemophilia A .

The trial’s main goal reduce bleeding rates compared with -demand treatment.

Hemophilia A, also called classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein.

in the twice-weekly prophylaxis, or preventive, arm of the trial experienced a 95 percent reduction in median yearly bleeding rates compared with those in the -demand arm, Baxter said.

The apply for U.S. marketing approval for the drug before the end of the year and said would begin another late-stage study test BAX 855 in previously treated under the age of 12.

[eap_ad_2]


Baxter raised the forecast for its hemophilia franchise in July, despite the potential for from Biogen Idec Inc’s long-acting treatment Eloctate, which the U.S. and Drug Administration approved in June.

BAX 855 is an extended-release version of Advate, which first approved a decade ago and is currently sold in 64 countries.

The experimental drug uses Nektar Therapeutics’ proprietary technology to extend the duration of activity of proteins in the body.

Deerfield, Illinois-based Baxter’s stock was about 1.2 percent on the Stock on . (Reuters)

[eap_ad_3]